![](/img/cover-not-exists.png)
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
Doria, A, Bass, D, Schwarting, A, Hammer, A, Gordon, D, Scheinberg, M, Fox, N L, Groark, J, Stohl, W, Kleoudis, C, Roth, DLanguage:
english
Journal:
Lupus
DOI:
10.1177/0961203318777634
Date:
May, 2018
File:
PDF, 274 KB
english, 2018